Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various skin side effects from chemotherapy, noting that they are mainly toxic rather than allergic and often include alopecia, which can cause significant distress to patients.

This review describes how cutaneous toxicity from kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics could potentially serve as a biomarker for anticancer treatment efficacy, but highlights the need for more extensive research to confirm this association.

This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.

This study found that glycyrrhizic acid may reduce the cutaneous toxicity caused by Osimertinib in mice, suggesting its potential as an adjunct treatment in clinical settings.